NQO1*2/*2, amphetamine exposure, and dopamine-quinone reserve: a minimum-dose and rescue hypothesis

This is a research/harm-reduction hypothesis, not personal medical advice. The actionable clinical claim is deliberately conservative: there is no validated "NQO1*2/*2-safe amphetamine dose." If amphetamine is used at all, the defensible framing is clinician-supervised minimum-effective-dose titration with cardiovascular, sleep, temperature, psychiatric, and functional monitoring, and a low threshold to prefer non-amphetamine options.

Hypothesis

NQO1*2/*2 (rs1800566 TT, P187S/P187S) should be treated as a low-margin dopamine-quinone detox state. Amphetamine does not need to be a direct NQO1 substrate to matter: it increases dopamine release and cytosolic/extravesicular dopamine pressure, which can increase dopamine oxidation chemistry. In a person with little functional NQO1 reserve, the relevant risk axis is not "does amphetamine dock to NQO1?" but "does the exposure create more dopamine o-quinone/aminochrome burden than the remaining detox network can buffer?"

So the core prediction is:

1. The safest amphetamine exposure is the smallest dose that gives a measurable functional benefit without sympathetic overactivation, insomnia, overheating, rebound, or repeated redosing.
2. Genotype alone cannot identify that dose.
3. Rescue should prioritize reducing dopamine-quinone formation and improving non-NQO1 buffering, because P187S is a coding stability/FAD-binding defect, not mainly an RNA-expression defect.

Why NQO1*2/*2 matters

The NQO1*2 allele encodes P187S. Literature and my local structural work agree on the broad mechanism: the variant is not just a mild active-site substitution; it compromises flavin-supported holo-state stability. Homozygous 609TT/*2/*2 is commonly treated as severely NQO1-deficient, with little or no enzyme activity reported in genotype studies.

NQO1 is relevant to dopamine neurons because dopamine oxidation can produce dopamine o-quinone, aminochrome, and downstream indolequinones. NQO1/DT-diaphorase can perform two-electron reduction of aminochrome toward leukoaminochrome, avoiding one-electron radical chemistry. Aminochrome is not a harmless marker: it has been linked to mitochondrial dysfunction, alpha-synuclein oligomerization, proteostasis stress, and oxidative stress. Methamphetamine/amphetamine-like neurotoxicity models repeatedly implicate dopamine release, dopamine quinones, ROS, hyperthermia, and microglial activation.

Local NQO1 computational synthesis

My local Boltz-2/analysis panel supports a "flavin-state-sensitive mutant" model rather than a dead-pocket model.

Baseline pathology:

• P187S + FAD + aminochrome still binds in a broad sense, but the cofactor-supported geometry is much less coherent than WT.
• WT FAD + aminochrome: FAD pairwise RMSD mean 0.236 A; aminochrome-FAD minimum distance mean 3.349 A; complex_ipde 0.591.
• P187S FAD + aminochrome: FAD pairwise RMSD mean 15.260 A; aminochrome-FAD minimum distance mean 7.219 A; complex_ipde 0.804.
• That reads as a cofactor-centered stress-state failure, not complete substrate-recognition loss.

Rescue-like signals:

• P187S + FMN and P187S + riboflavin were the cleanest standalone flavin-side states.
• The most disease-relevant rescue-like state remained P187S + FMN + aminochrome.
• P187S + FADH2 + dopamine o-quinone was the best geometry-first non-aminochrome follow-up: probe RMSD 2.627 A, probe-cofactor minimum distance 3.197 A.
• P187S + FMN + dopamine semiquinone proxy had a better confidence-style signal but loose geometry, so I treat it as exploratory.
• dicoumarol strongly clamped the mutant pocket but is an inhibitor, so it is a stabilizability control, not a therapy.
• BPPSA is interesting as a state-selector/chaperone hypothesis, especially with FMN, but the combined BPPSA + aminochrome states did not cleanly beat FMN + aminochrome.
• Consumer/drug-like add-ons (idebenone, MitoQ, quercetin/onion-style compounds) did not outrank the flavin-state hypotheses.
• Direct P187S + FAD + amphetamine had decent structure metrics but is an exploratory control only; it is not a serious NQO1 quinone-detox candidate and does not justify a dose.

RNA-side result:

• Phase-aware AlphaGenome-style local runs did not show a large NQO1 RNA/splice collapse: NQO1 RNA magnitude was only 0.039, while the main issue remains homozygous coding P187S.
• NQO2 was not RNA-down in that run.
• This argues against expecting simple NQO1 induction to fully solve the problem in *2/*2.

Minimum amphetamine dose: what can and cannot be said

What can be said:

• FDA labeling for mixed amphetamine salts says amphetamines should be administered at the lowest effective dosage and individualized to patient response.
• The lowest ordinary immediate-release tablet strength is 5 mg; labeling for ADHD in children 6+ starts at 5 mg once or twice daily with weekly 5 mg increments. Adult references often use the same 5 mg IR starting logic, while XR/lisdexamfetamine starts higher by formulation.
• If the goal is minimizing dopamine-quinone stress, IR may be easier to experimentally titrate than long-acting formulations, but it also creates peaks and redosing risk. This is a clinician-level tradeoff, not a DIY dosing instruction.

What cannot be said:

• No public evidence establishes that 5 mg, 2.5 mg, or any other amphetamine dose is "safe" specifically for NQO1*2/*2.
• My docking/structural panel cannot infer systemic neurotoxicity thresholds.
• A low dose with sleep loss, dehydration, heat exposure, MAOI interaction, high caffeine, or redosing could be riskier than a cleaner supervised exposure.

Practical research framing:

• Treat "lowest safe dose" as "lowest clinically useful dose under monitored conditions," not as a genotype-derived number.
• Predefine stop signals: insomnia, appetite suppression, resting tachycardia, blood-pressure rise, overheating, agitation, compulsive redosing, mood destabilization, or loss of next-day function.
• Prefer the exposure pattern that minimizes total daily dopaminergic pressure, avoids late-day dosing, avoids overheating, and does not require repeated rescue/redose cycles.

Rescue hierarchy

Most plausible near-term risk reducers:

1. Avoid unnecessary dopamine oxidation burden: no binge dosing, no sleep deprivation, no overheating, no dehydration, no MAOIs, no uncontrolled sympathomimetic stacking.
2. Use non-amphetamine ADHD options first when clinically acceptable: methylphenidate-class, atomoxetine, guanfacine/clonidine, bupropion, behavioral/environmental interventions. Each has its own risks, but they may reduce direct amphetamine-like dopamine-release pressure.
3. Support general redox capacity: adequate sleep, temperature control, nutrition, avoidance of smoke/solvents/pesticide/quinone load, and monitoring of iron/inflammation context if clinically relevant.
4. Nrf2/GSH-side support is plausible as a network strategy, but in NQO1*2/*2 it should not be sold as "restore NQO1." It may induce other antioxidant genes even if P187S protein remains unstable.
5. Flavin-side rescue is the most interesting mechanistic hypothesis from my computational work (FMN, riboflavin-like states, reduced flavin states), but this is not yet a clinical dosing recommendation.
6. Direct pharmacological chaperoning of P187S is scientifically plausible (BPPSA-like small molecule chaperone literature), but not a ready human intervention.

Falsification and next experiment

This hypothesis weakens if:

• NQO1*2/*2 carriers show no difference in dopamine-quinone/adduct or oxidative-stress readouts after controlled amphetamine exposure versus matched controls.
• Functional benefit from amphetamine is achieved without any dose-dependent redox/sympathetic penalty in careful N-of-1 monitoring.
• FMN/riboflavin/reduced-flavin structural rescue fails in explicit-solvent MD or biochemical assays.

The next useful experiment is not another broad docking sweep. It is a small, pre-registered panel:

• WT vs P187S biochemical NQO1 activity/stability with FAD, FMN/riboflavin-like conditions, and aminochrome/dopamine o-quinone stress.
• Short explicit-solvent MD for P187S + FAD + aminochrome, P187S + FMN + aminochrome, and P187S + FADH2 + dopamine o-quinone.
• If studying amphetamine clinically, use a clinician-supervised, minimum-effective-dose design with pre/post sleep, HR/BP, temperature, symptom, and oxidative/adduct biomarker readouts.

References

• NQO1 P187S compromises FAD binding/activity and stability: https://pubmed.ncbi.nlm.nih.gov/28771686/ and https://pmc.ncbi.nlm.nih.gov/articles/PMC4738246/
• NQO1*2 / C609T severe activity loss in TT genotype: https://pmc.ncbi.nlm.nih.gov/articles/PMC3472723/
• Dopamine oxidation/aminochrome/NQO1 neuroprotection: https://pubmed.ncbi.nlm.nih.gov/24548101/ and https://pubmed.ncbi.nlm.nih.gov/25634539/
• Methamphetamine/amphetamine-like dopamine quinone neurotoxicity: https://pubmed.ncbi.nlm.nih.gov/19897074/ and https://pmc.ncbi.nlm.nih.gov/articles/PMC6786023/
• Adderall label: lowest effective dosage, dose individualization, cardiac screening, BP/HR monitoring: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81